: Halo Therapeutics stock drops following weak 2023 outlook

0
12

Halozyme Therapeutics Inc. HALO, +1.20% stock fell in the extended session Tuesday after the biotech drug maker’s 2023 forecast disappointed Wall Street. Halozyme shares fell as much as 8% after hours, following a 1.2% gain to close the regular session at $55.70. The company forecast annual adjusted earnings of $2.50 to $2.65 a share on revenue of $815 million to $845 million with royalties of $445 million to $455 million. Analysts surveyed by FactSet had forecast $2.55 a share on revenue of $892.5 million with royalties of $478.2 million.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: The holiday PC market stunk for everyone except Apple, report says
Next articleLike the current rally in stocks? Enjoy it before you have to fret later in 2023

LEAVE A REPLY

Please enter your comment!
Please enter your name here